Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TruTag: Silica Microparticle Taggant System for ART Adherence
NCT06465862Withdrawn
- Sponsor
- Brigham and Women's Hospital
- Start
- Sep 2024
- Primary completion
- Dec 2024
01
Overview
Open-label, single-arm trial, sponsored by Brigham and Women's Hospital. Primary endpoints: Feasibility of TruTag to Measure Antiretroviral (ART) Adherence at 90 days, Acceptability of TruTag, via System Usability Scale at 90 days and 1 more. Planned start Sep 2024; status: withdrawn.
Beyond the preview
Go deeper on NCT06465862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06465862.